• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清对氧磷酶 1 异质体,一种糖基化的、岩藻糖基化和唾液酸化的糖蛋白,可用于区分早期肝细胞癌与肝硬化患者。

Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.

机构信息

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2012 Sep;44(9):765-73. doi: 10.1093/abbs/gms055. Epub 2012 Jul 1.

DOI:10.1093/abbs/gms055
PMID:22751611
Abstract

Aberrant glycan structure of serum glycoproteins creates unique patterns in different stages of hepatocellular carcinoma (HCC), which provides potential glycan biomarkers for early diagnosis of HCC. In this study, tandem lectin affinity chromatography using aleuria aurantia lectin (AAL) and wheat germ agglutinin (WGA) was processed to purify both fucosylated and sialylated serum glycoproteins from 27 liver cirrhosis (LC) and 27 early HCC patients, in which 122 glycoproteins were finally screened out by liquid chromatography-tandem mass spectrometry (LC-MSMS). Among the 122 proteins identified by LC-MSMS, 8 of them were only identified in HCC serum and another 6 existed only in LC serum. Serum paraoxonase 1 (PON1) was immunoprecipitated from 47 individual patients and blotted by lectins, showing enhanced fucosylation and sialylation in HCC serum than those in LC serum. The area under the ROC curve (AUROC) for AAL-reactive PON1 was 0.892 with a sensitivity of 71.4% and a specificity of 94.7% in differentiating early HCC from LC. Similarly, WGA-reactive PON1 had an AUROC of 0.902 with a sensitivity of 95.2% and a specificity of 78.9%. The data indicated that the glycan differences of serum PON1 might serve as potential glycan biomarkers for distinguishing early HCC from LC patients.

摘要

血清糖蛋白中异常的聚糖结构在肝细胞癌 (HCC) 的不同阶段产生独特的模式,为 HCC 的早期诊断提供了潜在的糖基生物标志物。在这项研究中,使用金耳凝集素 (AAL) 和麦胚凝集素 (WGA) 的串联凝集素亲和层析法从 27 名肝硬化 (LC) 和 27 名早期 HCC 患者中纯化了糖基化和唾液酸化的血清糖蛋白,最终通过液相色谱-串联质谱 (LC-MSMS) 筛选出 122 种糖蛋白。在通过 LC-MSMS 鉴定的 122 种蛋白质中,有 8 种仅在 HCC 血清中鉴定,另外 6 种仅在 LC 血清中存在。从 47 名个体患者中提取血清对氧磷酶 1 (PON1) 并通过凝集素印迹,结果显示 HCC 血清中的糖基化和唾液酸化程度高于 LC 血清。AAL 反应性 PON1 的 ROC 曲线下面积 (AUROC) 为 0.892,区分早期 HCC 与 LC 的灵敏度为 71.4%,特异性为 94.7%。同样,WGA 反应性 PON1 的 AUROC 为 0.902,灵敏度为 95.2%,特异性为 78.9%。数据表明,血清 PON1 的聚糖差异可能作为区分早期 HCC 与 LC 患者的潜在聚糖生物标志物。

相似文献

1
Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.血清对氧磷酶 1 异质体,一种糖基化的、岩藻糖基化和唾液酸化的糖蛋白,可用于区分早期肝细胞癌与肝硬化患者。
Acta Biochim Biophys Sin (Shanghai). 2012 Sep;44(9):765-73. doi: 10.1093/abbs/gms055. Epub 2012 Jul 1.
2
Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.血清岩藻糖基化对氧磷酶1作为一种潜在的糖生物标志物,用于酶联免疫吸附测定法早期肝细胞癌的临床诊断。
Glycoconj J. 2015 May;32(3-4):119-25. doi: 10.1007/s10719-015-9576-8. Epub 2015 Feb 22.
3
Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.使用岩藻糖基化对氧磷酶1诊断甲胎蛋白阴性的早期肝细胞癌
Discov Med. 2017 Mar;23(126):163-168.
4
Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.表面增强激光解吸/电离质谱分析:乙肝相关肝细胞癌的新诊断方法。
J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.
5
Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.基于岩藻糖基化糖蛋白的血清谱分析用于鉴别慢性乙型肝炎和肝细胞癌。
Biochem Biophys Res Commun. 2012 Apr 6;420(2):308-14. doi: 10.1016/j.bbrc.2012.02.155. Epub 2012 Mar 7.
6
Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients.
Biochem Biophys Res Commun. 2008 Sep 19;374(2):219-25. doi: 10.1016/j.bbrc.2008.06.124. Epub 2008 Jul 11.
7
Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.血清触珠蛋白及其糖型在肝细胞癌诊断中的研究:一种糖蛋白质组学方法
J Proteome Res. 2006 Oct;5(10):2691-700. doi: 10.1021/pr060109r.
8
[Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma].[血清高尔基体驻留糖蛋白GP73作为肝细胞癌诊断标志物的检测与评估]
Zhonghua Zhong Liu Za Zhi. 2010 Dec;32(12):943-5.
9
Multifucosylated Alpha-1-acid Glycoprotein as a Novel Marker for Hepatocellular Carcinoma.多岩藻糖基化α-1-酸性糖蛋白作为肝细胞癌的新型标志物
J Proteome Res. 2016 Sep 2;15(9):2935-44. doi: 10.1021/acs.jproteome.5b01145. Epub 2016 Aug 9.
10
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.血清高尔基糖蛋白-3在鉴别肝细胞癌与非恶性慢性肝病和其他肝癌中的诊断作用。
J Gastroenterol Hepatol. 2010 Jan;25(1):129-37. doi: 10.1111/j.1440-1746.2009.05988.x. Epub 2009 Sep 27.

引用本文的文献

1
Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma.术前血清聚糖水平反映肝癌患者的进展情况。
Cancer Med. 2024 Oct;13(19):e70285. doi: 10.1002/cam4.70285.
2
Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.肝细胞癌的新兴及临床认可的生物标志物
Cancers (Basel). 2024 Apr 10;16(8):1453. doi: 10.3390/cancers16081453.
3
Integrating transcriptomics, glycomics and glycoproteomics to characterize hepatitis B virus-associated hepatocellular carcinoma.整合转录组学、糖组学和糖蛋白质组学来表征乙型肝炎病毒相关的肝细胞癌。
Cell Commun Signal. 2024 Apr 1;22(1):200. doi: 10.1186/s12964-024-01569-y.
4
Serum Activities of Paraoxonase 1 (PON1) in Predicting Liver Damage Among Patients Diagnosed With Hepatocellular Carcinoma: A Case-Control Study.对氧磷酶1(PON1)血清活性在预测肝细胞癌患者肝损伤中的作用:一项病例对照研究。
Cureus. 2023 Sep 29;15(9):e46234. doi: 10.7759/cureus.46234. eCollection 2023 Sep.
5
Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications.肝细胞癌中的蛋白质糖基化改变:功能及临床意义
Oncogene. 2023 Jun;42(24):1970-1979. doi: 10.1038/s41388-023-02702-w. Epub 2023 May 16.
6
Multi-targeted therapy resistance via drug-induced secretome fucosylation.通过药物诱导的外泌体岩藻糖化导致多靶点治疗耐药性。
Elife. 2023 Mar 24;12:e75191. doi: 10.7554/eLife.75191.
7
New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.用于诊断甲胎蛋白阴性肝细胞癌的新型血液生物标志物
Front Oncol. 2020 Aug 14;10:1316. doi: 10.3389/fonc.2020.01316. eCollection 2020.
8
Biomarkers for the Early Detection of Hepatocellular Carcinoma.用于肝细胞癌早期检测的生物标志物。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2495-2503. doi: 10.1158/1055-9965.EPI-20-0005. Epub 2020 Apr 1.
9
Chemiluminescent detection of glycocode alterations in hepatic granulomatous lesions of experimental schistosomiasis.实验性血吸虫病肝肉芽肿病变中糖码改变的化学发光检测
Int J Clin Exp Pathol. 2017 Aug 1;10(8):8599-8604. eCollection 2017.
10
Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer.鉴定一种新型临床生物标志物,用于人类非小细胞肺癌的早期诊断。
Glycoconj J. 2019 Feb;36(1):57-68. doi: 10.1007/s10719-018-09853-z. Epub 2019 Jan 3.